Ruxolitinib Amide | CAS 2102675-42-1 - Request Quote
Ruxolitinib Amide
| SZ CAT No: | SZ-R044044 |
| CAS No | 2102675-42-1 |
| Mol.F. | C17H20N6O |
| Mol.Wt. | 324.4 |
| Inv. Status | In Stock |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Ruxolitinib Amide is chemically (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanamide. Ruxolitinib Amide is supplied with detailed characterization data compliant with regulatory guideline. Ruxolitinib Amide can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ruxolitinib.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 2102675-42-1
Purchase 2102675-42-1
Order 2102675-42-1
Enquire 2102675-42-1
price of 2102675-42-1
2102675-42-1 Supplier
2102675-42-1 Manufacturer
2102675-42-1 Exporter
buy high quality Ruxolitinib Amide
Purchase Ruxolitinib Amide
Ruxolitinib Amide suppliers
Ruxolitinib Amide manufacturers
Ruxolitinib Amide price
Order Ruxolitinib Amide
Enquire Ruxolitinib Amide
Ruxolitinib Amide cost
Ruxolitinib Amide Supplier
Ruxolitinib Amide Distributor
Ruxolitinib Amide for Method Validation
Ruxolitinib Reference Standard
Ruxolitinib Amide for ANDA Filing
Ruxolitinib Amide for Forced Degradation Studies
Ruxolitinib Amide Identification Standards
Ruxolitinib Amide for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


